The COVID-19 pandemic has compelled regulatory agencies across the globe to offer some degree of flexibility in clinical trial processes to support ongoing research without compromising patient safety, data quality and data integrity.
Regulators in the US and the EU have done the same, but with “significant differences” in relation to remote source...